Adial Pharmaceuticals Inc (ADIL) News
Follow Adial Pharmaceuticals Inc (ADIL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Adial Pharmaceuticals appoints David Rubenstein chief scientist
David Rubenstein, M.D., Ph.D., was appointed chief scientist to advance AT177, a colon-targeted AhR agonist for ulcerative colitis.
EQUITY | Oct 16, 2026, 11:00 AM UTC
L
Adial Pharmaceuticals announces Nasdaq inducement grant under Rule 5635(c)(4)
Adial Pharmaceuticals (ADIL) announces an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Aug 25, 2026, 08:05 PM UTC
L
Adial Pharmaceuticals reports 2026 Q2 financial results; business update
Adial Pharmaceuticals (ADIL) reports 2026 second quarter financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 17, 2026, 11:00 AM UTC
M
ADIL Initiated Buy
Alliance Global Partners initiates ADIL buy
EQUITY | Aug 03, 2026, 11:48 AM UTC
L
ADIL: Files SC 13G
ADIL files SC 13G
EQUITY | Jun 24, 2026, 02:36 PM UTC